Evaluation of the SH-SY5Y cell line as an in vitro model for potency testing of a neuropeptide-expressing AAV vector

• Jeanette Zanker,
• Daniela Hüser,
• Adrien Savy,
• Sara Lázaro-Petri,
• Eva-Maria Hammer,
• Christoph Schwarzer,
• Regine Heilbronn

Affiliations

Jeanette Zanker

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Daniela Hüser

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Adrien Savy

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Sara Lázaro-Petri

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Eva-Maria Hammer

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Christoph Schwarzer

Institute of Pharmacology, Medical University of Innsbruck, Innsbruck, Austria

Regine Heilbronn

Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany